Crizotinib Holds Promise For Lung Cancer, And For Pfizer Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
The targeted ALK inhibitor is on an accelerated track, with initial Phase I unveiled at ASCO annual meeting and a registration program already under way.